NCT06764628

A Study of SHR-4375 in Subjects With Solid Tumors

An Open-label, Single-arm, Multicenter Phase I/II Clinical Study of SHR-4375 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 208 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	SHR-4375	SHR-4375 injection

Timeline

• Start date: 2025-01-09
• Primary completion: 2027-05-01
• Completion: 2027-05-01
• First posted: 2025-01-08
• Last updated: 2025-01-22

Locations

1 site across 1 country: China